Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioInvent International AB ( (SE:BINV) ) has issued an announcement.
BioInvent International AB announced promising Phase 1 clinical data for its TNFR2 agonist antibody, BI-1910, presented at the SITC 2025 Annual Meeting. The study showed that BI-1910 can activate immune responses and induce disease control in patients with advanced solid tumors, with 12 out of 26 patients achieving stable disease. Despite these positive results, BioInvent has paused the development of BI-1910 to focus on its more advanced program, BI-1808, which is progressing in Phase 2 clinical development.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer therapy. The company is engaged in ongoing clinical programs with drug candidates in Phase 1/2 trials.
Average Trading Volume: 102,171
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.19B
Find detailed analytics on BINV stock on TipRanks’ Stock Analysis page.